Servier licenses Galapagos Phase 1 drug for osteoarthritis and IBD in deal worth $340.4M. Gild partnered Galapagos's Filgotinib currently in Phase 3 for Ulcerative Colitis in $725M deal. BP has no interest in arna old pipe. Arna can't compete.
Arena got more money and shareholders got hoodwinked again...ARENA HAS BEEN DOING THIS FOR MORE THAN 20 YEARS AND NOTHING HAS CHANGED...NOTHING, NADA, ZILCH...WHY CHANGE A SUCCESSFUL FORMULA? dyodd
Have received many emails, Friends, asking why 5 Underwriters, why not a loan that is better for shareholders rather than adding shares that dilute shareholder/owner value. Simple, arna couldn't afford a loan with it's weighted avg cost of capital at 13.55% which is 9.3 points higher than prime. Especially w/it's Return on Capital of - 618.32%. Only option is dilution. Needed 5 Banks to run it cause underwriting arna is too risky for 1,2,3 or 4. Underwriters needed to spread risk. Well, Tues July 25th 2017 had 70.1% of trades shorting arna. Ouch!. Don't trust pumpers, they lie, distort and mislead. Check for ticks. Stay tuned and Cheers!!
When the 5 Underwriter Banks shut down their support algos pps will fall like a rock.
ARNA longs and pumpers rejoice in 20 years of unprofitability. Give high fives on having just 1 approved drug, a very poor selling diet pill, in 20 years. Dance about dilutions being life source. Raise their arms in the air rejoicing in their losses as only insiders make millions. Hallelujah!
Underwriter banksters fighting hard to prop pps to dump their discounted shares.
Underwriters dropping support...soon!!
Aww...PPS Up a WHOPPING .002 cents!! Whopper Flippers Pretend Reverse Split Never Happened. WOO HOO! Sharing OREO Flurries Believing the 5 Banksters ARE NOT doing all they can to KEEP PPS THIS HIGH . Whopper Flippers WHOOPING happy about ATM Dilution starting in JAN, getting DILUTED 24% in APRIL, HAVING Shares 1:10 RS in JUNE then DILUTED again in JULY. WOO HOO!!
Gang of 5 Banksters having hard time getting rid of shares. PPS just hovering at offering price. Bad news, but expected. Wise investors know junk can't be hidden by smoke and mirrors.
Friends, well pps went up 0.029 pennies on Monday July 24, 2017 taking into account the recent 1:10 Reverse Split. Longs seem angry and disappointed as the well should with all the lies and distortions pumpers and promoters feed them. On Monday 67.3% of trades shorted Arna. Don't trust pumpers. Remember so-called pipe is old, tiny, delayed and unwanted. If you go out of doors check for ticks. They're nasty disease carriers. Stay tuned. Cheers!
A couple of more items about ancient Etrasimod. The EPRSQ guy who leads ARNA now and flooded our beloved company with EPRSQ peeps goofed up by getting rid of top scientists and Dominic. That has really critically slowed apd334 progress almost to the point that it's doom is practically guaranteed. Our company has filed with SEC numerous times indicating that other patents will jeopardize commercialization of Etrasimod. Besides CELG, other BP"S have gone past this old, delayed research drug. Just today LLY partnered for a sum of $400M with a basically preclinical drug from NKTR for autoimmune diseases of IBD and others.
PPS up on 200 shares. Looks like low volume pre-market pps manipulation to trick you to buy. 5 Underwriters playing share ping pong to jack the pps as they try to unload their discounted shares. No reason to buy. Anything you buy can and will be used against you. Diluted Trapped Longs have no chance of re-couping losses. 3 dilutions and RS in seven months. Don't fall for underwriter tricks. Dyodd
AWW...Up a WHOPPING .001 cents! WHOPPER FLIPPERS splitting OREO Flurry's to celebrate.
big name backers: AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly, Johnson & Johnson Innovation, Watson Fund, WRF Capital and WuXi AppTec help start-up Rodeo Therapeutics that's working on ulcerative colitis and other diseases. AbbVie, Lilly and JNJ ignore arna for UC.
NOW LET's REVIEW THE RECENT EVENTS...WHO GOT THE MONEY AND WHO GOT SCREWED AGAIN FOR THE UMTEENTH TIME...THE 1 FOR 10 REVERSE WORKED OK AND OF COURSE THE SECONDARY WAS A TREMENDOUS SUCCESS FOR INSIDERS WHO GOT $150,000,000.00 PLAY MONEY RESULTING IN SALARY INCREASES, CASH BONUSES AND MORE OPTIONS FOR INSIDERS WHO CONGRATULATE EACH OTHER WITH LAVISH REWARDS AND OF COURSE SHAREHOLDERS GOT DILUTED AND SCREWED AGAIN...HISTORICALLY SPEAKING ARENA HAS BEEN SUCCESSFULLY USING THIS FORMULA FOR MORE THAN 20 YEARS WITHOUT ANY CONSEQUENCES WHATSOEVER...WHY CHANGE SUCH A SUCCESSFUL FORMULA THAT REWARDS INSIDERS AND SCREWS SHAREHOLDERS? dyodd
620 pre-market share trades.Looks like low volume pre-market pps manipulation to trick you to buy. 5 Underwriters playing share ping pong to jack the pps as they try to unload their discounted shares. No reason to buy. Anything you buy can and will be used against you. Trapped Diluted Longs can't recover massive losses. DYODD
Friends, you'd be well advised to not put any stock in the pumper noise of buyout or acquiring pipeline pieces or whole. For those newbies this buyout ploy has been used for over a decade by criminal pumpers. There's no value to the pipe. BP has checked it and passed. On Thurs July 20th 37.5% of trades went short and on Fri July 21 40.3% of trades shorted. Count on pps falling soon as the 5 Investment Bank Underwriters start ending their support that's keeping pps artificially high. Remember don't trust pumpers or desperate underwater longs. Check for ticks if you go outdoors. Stay tuned. Cheers!!
Lilly joins other BP's in skipping ARNA for Autoimmune diseases like UC, Crohns and others. Partners with Nektar Therapeutics Phase 1 autoimmune research drug. BP has no interest in ARNA's old, delayed, pipe. Arna can't compete.
KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.
Looks like the 5 Underwriters are doing low volume shenanigans with pps to trick you to buy. Don't fall for underwriter tricks. Arna not worth $1.50 let alone the Reverse Split pps at now. Anything you buy can and will be used against you. DYODD